Loading...
•
Sep 30, 2025
Omeros Q3 2025 Earnings Report
Omeros posted a reduced net loss in Q3 2025, supported by lowered operating expenses and royalty income from OMIDRIA.
Key Takeaways
Omeros narrowed its quarterly net loss year-over-year, improved cash position through equity raises, and maintained moderate operating expenses ahead of a potentially transformative product launch.
Net loss for Q3 2025 was $30,917,000 or $0.47 per share.
Non-GAAP net loss was $22,095,000 or $0.34 per share.
OMIDRIA royalties were $9,200,000 on $30,500,000 in U.S. net sales.
Cash and short-term investments totaled $36,085,000 at quarter-end.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Omeros expects a transformative Q4 2025 pending the closing of a major licensing deal and FDA approval for narsoplimab.
Positive Outlook
- Anticipates $240M cash infusion from Novo Nordisk deal closing in Q4.
- FDA decision for narsoplimab expected by December 26, 2025.
- Operational cost control reduced quarterly expenses by $9M YoY.
- Published positive peer-reviewed clinical data on narsoplimab.
- Received $29.3M in gross equity financing in Q3 2025.
Challenges Ahead
- Continued net and operating losses.
- Discontinued operations posted $9.7M net loss.
- Cash burn of $22M in Q3 exclusive of financing proceeds.
- High debt obligations remain including royalty and notes.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...